Company: IMCR
Filing Date: 2025-01-02
Form Type: 8-K
Source: 0001140361-25-000008
Chunk: 0

Company: Immunocore Holdings plc
Filing Date: 2025-01-02
Form: 8-K
Item: Item 5.02
Chunk 0
---
Item 5.02.      Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.  

Appointment of New Chief Financial Officer

On December 31, 2024, Immunocore LLC, an indirect, wholly owned subsidiary of Immunocore Holdings plc (“ Parent” and, together with Immunocore LLC, the
“ Company”), entered into an employment agreement (the “ Employment Agreement”) with Travis Coy, pursuant to which Mr. Coy will serve as the Company’s Executive Vice President, Chief Financial Officer and Head of Corporate Development as well as the
Company’s principal financial officer, effective as of January 1, 2025 (the “ Effective Date”). In connection with his entry into the Employment Agreement, Mr. Coy resigned from the Company’s board of directors (the “ Board”), effective as of the
Effective Date.

Mr. Coy, age 44, previously served as Vice President, Head of Transactions and M& A, Corporate Business Development at Eli Lilly and Company
(“ Lilly”), a position he held since October 2019. Prior to this role, Mr. Coy held a variety of finance and business development experiences of increasing responsibility at Lilly since he joined in 2003, including positions as Vice President,
Transactions - Oncology and Diagnostics; Vice President, Transactions - Cardiometabolic Diseases, Drug Delivery and Devices; Finance Director of the Oncology Business Unit; Director of Investor Relations; Director of Corporate Finance and Investment
Banking; and other financial controllership roles. Before transitioning to finance and business development, he served as a chemist in Lilly’s research laboratories and as a production manager for Milliken & Company. Mr. Coy holds an M. B. A. from
the Ross School of Business at the University of Michigan and a B. S. in Chemistry from Rose-Hulman Institute of Technology.

Pursuant to the Employment Agreement, Mr. Coy will receive an initial annual base salary of $500,000 per year and be eligible to receive an annual cash
performance bonus with a target amount equal to 40% of his annual base salary. Mr. Coy will also receive a cash sign-on bonus of $200,000, payable in three installments as follows: $100,000 payable on January 31, 2025, and $50,000 payable on each of
January 30, 2026 and January 29, 2027, subject to Mr. Coy